Cargando…

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma

Protein homeostasis is critical for maintaining eukaryotic cell function as well as responses to intrinsic and extrinsic stress. The proteasome is a major portion of the proteolytic machinery in mammalian cells and plays an important role in protein homeostasis. Multiple myeloma (MM) is a plasma cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Yanyan, Barwick, Benjamin G., Shanmugam, Mala, Hofmeister, Craig C., Kaufman, Jonathan, Nooka, Ajay, Gupta, Vikas, Dhodapkar, Madhav, Boise, Lawrence H., Lonial, Sagar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736847/ https://www.ncbi.nlm.nih.gov/pubmed/33318477 http://dx.doi.org/10.1038/s41408-020-00393-0

Ejemplares similares

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
por: Barwick, Benjamin G., et al.
Publicado: (2019)

β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
por: Schmidt, Timothy M., et al.
Publicado: (2019)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

Venetoclax ex vivo functional profiling predicts improved progression-free survival
por: Gupta, Vikas A., et al.
Publicado: (2022)

Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience
por: Maples, Kathryn T., et al.
Publicado: (2023)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

PA28αβ: The Enigmatic Magic Ring of the Proteasome?
por: Cascio, Paolo
Publicado: (2014)

Structure, Function, and Allosteric Regulation of the 20S Proteasome by the 11S/PA28 Family of Proteasome Activators
por: Thomas, Taylor, et al.
Publicado: (2023)

PA28γ: New Insights on an Ancient Proteasome Activator
por: Cascio, Paolo
Publicado: (2021)

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P G, et al.
Publicado: (2017)

Proteasome activator 28γ (PA28γ) allosterically activates trypsin-like proteolysis by binding to the α-ring of the 20S proteasome
por: Thomas, Taylor A., et al.
Publicado: (2022)

Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
por: Bajpai, Richa, et al.
Publicado: (2020)

Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity
por: Moreno, Alberto, et al.
Publicado: (2023)

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
por: Richardson, P. G., et al.
Publicado: (2018)

Proteasome activators, PA28γ and PA200, play indispensable roles in male fertility
por: Huang, Lin, et al.
Publicado: (2016)

The role of proteasome activators PA28αβ and PA200 in brown adipocyte differentiation and function
por: Koçberber, Zeynep, et al.
Publicado: (2023)

Proteasome Activators, PA28α and PA28β, Govern Development of Microvascular Injury in Diabetic Nephropathy and Retinopathy
por: Yadranji Aghdam, Saeed, et al.
Publicado: (2016)

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth
por: Deng, Jiusheng, et al.
Publicado: (2016)

Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor in Multiple Myeloma
por: Gutman, Delia, et al.
Publicado: (2009)

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation
por: Shah, Shardule P., et al.
Publicado: (2016)

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy
por: Robinson, M. Hope, et al.
Publicado: (2023)

Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Cryo-EM of mammalian PA28αβ-iCP immunoproteasome reveals a distinct mechanism of proteasome activation by PA28αβ
por: Chen, Jinhuan, et al.
Publicado: (2021)

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
por: Nooka, Ajay K., et al.
Publicado: (2022)

Increased proteasome activator 28 gamma (PA28γ) levels are unspecific but correlate with disease activity in rheumatoid arthritis
por: Gruner, Melanie, et al.
Publicado: (2014)

The Proteasome Activators Blm10/PA200 Enhance the Proteasomal Degradation of N-Terminal Huntingtin
por: Aladdin, Azzam, et al.
Publicado: (2020)

MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma
por: Wang, Dongxue, et al.
Publicado: (2017)

Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28
por: van Hall, Thorbald, et al.
Publicado: (2000)

Removal of damaged proteins during ES cell fate specification requires the proteasome activator PA28
por: Hernebring, Malin, et al.
Publicado: (2013)

Proteasome activator PA28γ-dependent degradation of coronavirus disease (COVID-19) nucleocapsid protein
por: Zhang, Haiyang, et al.
Publicado: (2020)

Conformational maps of human 20S proteasomes reveal PA28- and immuno-dependent inter-ring crosstalks
por: Lesne, Jean, et al.
Publicado: (2020)

Structural insights into the human PA28–20S proteasome enabled by efficient tagging and purification of endogenous proteins
por: Zhao, Jianhua, et al.
Publicado: (2022)

Proteasome activator PA200 regulates myofibroblast differentiation
por: Welk, Vanessa, et al.
Publicado: (2019)

The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma
por: Findlay, Steven, et al.
Publicado: (2023)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
por: Ito, Shigeki
Publicado: (2020)

Hepatitis C virus core protein activates proteasomal activator 28 gamma to downregulate p16 levels via ubiquitin-independent proteasomal degradation
por: Cha, Sungkyung, et al.
Publicado: (2021)

Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
por: Zhang, Zhuo, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_fhjbuno5umtofit8uttfijpdgq